Monday, October 19, 2026 from 1:45 p.m. to 3:15 p.m. MDT at Salt Palace Convention Center - Ballroom J
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-26-170-L01-PActivity Type: An Application-Based ActivityBronchiectasis is an underrecognized chronic airway disease characterized by a cycle of chronic infection, recurrent inflammation, mucus hypersecretion, and respiratory exacerbations. Pharmacists often face a widening knowledge gap in understanding its heterogeneous pathophysiology, phenotyping, and rapidly evolving pharmacologic management. This gap is driven by increasing diagnosis rates and new therapeutic updates, including hypertonic saline nebulization strategies and the recent approval of brensocatib. This presentation will be organized into three sections: (1) pathophysiology and phenotyping, (2) updates in acute and chronic management, and (3) key considerations in chronic Pseudomonas aeruginosa and nontuberculous mycobacterial infection management. This proposed session aligns with ACCP’s commitment to advancing pharmacy practice and reducing health disparities through evidence-based care, particularly for underrecognized conditions such as bronchiectasis. The Pulmonary PRN aims to enhance pharmacist awareness of this heterogeneous disease by highlighting important, practice-changing updates. In addition, this presentation will broaden our target audience by incorporating infectious disease considerations, given the high prevalence of chronic Pseudomonas and nontuberculous mycobacteria colonization in this patient population.
Learning Objectives1. Describe the cycle of inflammation, infection, epithelial dysfunction, and lung structure damage that underlies bronchiectasis.
2. Differentiate the various etiologies of non–cystic fibrosis bronchiectasis based on patient specific factors.
3. Compare the effectiveness of available airway clearance therapies for patients with bronchiectasis.
4. Recommend the appropriate use of brensocatib based on patient specific factors and available evidence from clinical trials.
5. Formulate an appropriate antimicrobial therapy for P. aeruginosa infections in bronchiectasis patients, including acute exacerbations and chronic suppressive therapy.
6. Design a multi-antimicrobial drug therapy plan for patients with nontuberculous mycobacteria infection based on cultures, patient factors, and current guidelines.
 | | Moderator: | Paul J. Solinsky, Pharm.D., BCACP, AE-C | | Clinical Associate Professor of Pharmacy Practice
University of Maryland School of Pharmacy
Baltimore, Maryland
Clinical Pharmacist
Baltimore Washington Medical Center - Pulmonary Care
Glen Burnie, Maryland | | View Biography |
|
Bronchiectasis: Current Understanding of Pathophysiology and Disease Phenotypes 1:45 p.m. to 2:15 p.m. | | Speaker: | Lauren M. Simonds, Pharm.D., BCIDP, BCPS |
|
|
Chronic Bronchiectasis Management: Airway Clearance and Exacerbation Reduction Strategies 2:15 p.m. to 2:45 p.m. | | Speaker: | Andrea M. Nei, Pharm.D., BCCCP, BCPS | | Andrea Nei, PharmD., BCPS, BCCCP
Clinical Pharmacist - Pulmonary Medicine, Mayo Clinic, ***, Rochester, MN
| | View Biography |
|
|
Management of Acute and Chronic Infections in Bronchiectasis2:45 p.m. to 3:15 p.m. | | Speaker: | Christo L. Cimino, Pharm.D., BCIDP |
|
|